Publications by Professor John Isaacs - ePrints

Browsing publications by Professor John Isaacs.

Newcastle Authors	Title	Year
Professor John Isaacs	A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures	2024
Professor John Isaacs Dr Arthur Pratt Professor Christopher Buckley	Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial	2024
Philip Brown Dr Amy Anderson Najib Naamane Dr Dennis Lendrem Professor John Isaacs et al.	Adenosine metabolic signature in circulating CD4+ T cells predicts remission in rheumatoid arthritis	2024
Professor John Isaacs	CAR T Cells - A New Horizon for Autoimmunity?	2024
Professor John Isaacs	HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis	2024
Dr Abi Gault Dr Linda Hogarth Dr Kristian Williams Professor Alastair Greystoke Professor Neil Rajan et al.	Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study	2024
Dr Leher Gumber Dr Opeyemi Agbeleye Alex Inskip Ross Fairbairn Madeleine Still et al.	Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions	2024
Professor John Isaacs Dr Arthur Pratt Dr Elena Nikiphorou	Personalised care packages for people with rheumatoid arthritis: a mixed-methods study	2024
Professor John Isaacs	Population Pharmacokinetic Analysis and Simulation of Alternative Dosing Regimens for Biosimilars to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis	2024
Alice Lin Professor John Isaacs Dr Faye Cooles	Role of IFN-α in Rheumatoid Arthritis	2024
Dr Ken Baker Dr David McDonald Dr Gill Hulme Raf Hussain Dr Jonathan Coxhead et al.	Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remission	2024
Professor John Isaacs	Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023	2024
Professor Marieke Emonts-le Clercq Ashley Bell Kathryn Bell Dr Daniel Fabian Professor John Isaacs et al.	Adeno-associated virus 2 infection in children with non-A–E hepatitis	2023
Gemma Vidal Pedrola Najib Naamane Dr Arthur Pratt Emeritus Professor Andrew Mellor Professor John Isaacs et al.	Characterization of age-associated B cells in early drug-naïve rheumatoid arthritis patients	2023
Professor John Isaacs	Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update	2023
Professor John Isaacs	Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance	2023
Professor John Isaacs	EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases	2023
Professor Marieke Emonts-le Clercq Kathryn Bell Professor John Isaacs Dr Emma Lim Owen Treloar et al.	Genomic investigations of unexplained acute hepatitis in children	2023
Professor John Isaacs	Opportunistic infections associated with Janus kinase inhibitor treatment for rheumatoid arthritis: A structured literature review	2023
Professor John Isaacs	Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis	2023
Dr Josh Bennett Dr Arthur Pratt Dr Richard Dodds Professor Avan Sayer Professor John Isaacs et al.	Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis	2023
Professor John Isaacs	The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort	2023
Professor John Isaacs	Unmet need in rheumatology: Reports from the Advances in Targeted Therapies meeting, 2022	2023
Dr Arthur Pratt Professor John Isaacs Dr Elena Nikiphorou	Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review	2022
Dr Ken Baker Dr Dennis Lendrem Adam Scadeng Dr Ben Thompson Dr Arthur Pratt et al.	Erratum to "Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study" [J. Autoimmun. 105 (December 2019) 102298	2022
Dr Fiona Cooke Dr Mary Neal Dr Matthew Wood Dr Amy Anderson Julie Diboll et al.	Fluorine labelling of therapeutic human tolerogenic dendritic cells for 19F-magnetic resonance imaging	2022
Dr Arthur Pratt Professor John Isaacs	Impact of the COVID-19 pandemic on recruitment to clinical research studies in rheumatology	2022
Dr Faye Cooles Dr Jessica Tarn Dr Dennis Lendrem Najib Naamane Alice Lin et al.	Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming	2022
Alice Lin Dr Faye Cooles Professor John Isaacs	Precision medicine: the precision gap in rheumatic disease	2022
Professor James Wason Dr Arthur Pratt Professor John Isaacs Dr Elena Nikiphorou	Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?	2022
Professor John Isaacs Sarah Brockbank Dr Ayako Pedersen Professor Catharien Hilkens Dr Amy Anderson et al.	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients	2022
Dr Faye Cooles Professor John Isaacs	The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease	2022
Professor James Wason Dr Arthur Pratt Professor John Isaacs	The role of comorbidities alongside patient and disease characteristics on long-term disease activity in RA using UK inception cohort data	2022
Dr Fiona Rayner Dr Amy Anderson Dr Ken Baker Professor Christopher Buckley Dr Bernard Dyke et al.	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study	2021
Dr Ken Baker JASMINE Sim Por Xin Professor John Isaacs	Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?	2021
Professor John Isaacs	Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials	2021
Professor John Isaacs	Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment (Arthritis Research & Therapy, (2021), 23, 1, (80), 10.1186/s13075-021-02451-9)	2021
Professor John Isaacs	EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19	2021
Dr Ken Baker Dr Arthur Pratt Professor John Isaacs	Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Disease Flare in Patients with Rheumatoid Arthritis	2021
Professor John Isaacs	Immunogenicity of biologic agents in rheumatology	2021
Dr Dennis Lendrem Professor John Isaacs	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma	2021
Dr Nicola Maney Dr Ben Barron-Millar Dr Christopher Carey Ian Herron Dr Amy Anderson et al.	Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis	2021
Professor John Isaacs Dr Arthur Pratt	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial	2021
Dr Andrew Porter Dr Dennis Lendrem Professor John Isaacs	Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach	2021
Dr Arthur Pratt Dr Stefan Siebert Mike Cole Dr Deborah Stocken Amy Cranston et al.	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial	2021
Dr Arthur Pratt Professor John Isaacs Dr Elena Nikiphorou	The use and context of the term 'multimorbidity' in rheumatoid arthritis: A systematic literature review	2021
Mike Cole Professor Fai Ng Dr Stefan Siebert Dr Arthur Pratt Professor John Isaacs et al.	TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis	2021
Professor John Isaacs	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment	2021
Professor John Isaacs	Why remission is not enough: underlying disease mechanisms in RA that prevent cure	2021
Professor John Isaacs Professor Iain McInnes	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2	2020
Professor John Isaacs	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents	2020
Dr Jessica Tarn Dr Dennis Lendrem Professor John Isaacs	In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis	2020
Dr Ken Baker Benjamin Thompson Dr Dennis Lendrem Adam Scadeng Dr Arthur Pratt et al.	Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis remission	2020
Professor John Isaacs	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs	2020
Alex Clark Dr Amy Anderson Dr Nishanthi Thalayasingam Najib Naamane Julie Diboll et al.	Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci	2020
Professor John Isaacs	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score	2020
Dr Dennis Lendrem Dr Clare Lendrem Dr Arthur Pratt Professor John Isaacs Professor David Jones et al.	Schrödinger's pipeline and the outsourcing of pharmaceutical innovation	2020
Dr Lilian Nwosu Dr Arthur Pratt Professor John Isaacs	Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis	2020
Professor John Isaacs	Smart battles: Immunosuppression versus immunomodulation in the inflammatory RMDs	2020
Dr Stefan Siebert Dr Arthur Pratt Dr Deborah Stocken Dr Miranda Patterson Amy Cranston et al.	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial	2020
Professor John Isaacs Professor Iain McInnes	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities	2020
Dr James Stanway Professor John Isaacs	Tolerance-inducing medicines in autoimmunity: rheumatology and beyond	2020
Dr Ken Baker Professor John Isaacs Dr Ben Thompson	“Living a normal life”: a qualitative study of patients’ views of medication withdrawal in rheumatoid arthritis	2019
Professor John Isaacs Dr Arthur Pratt	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol	2019
Professor John Isaacs	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39	2019
Dr Clare Lendrem Dr Dennis Lendrem Dr Arthur Pratt Najib Naamane Dr Peter McMeekin et al.	Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic	2019
Adham Mousa Professor John Isaacs Dr David Price Dr Pallav Bhatnagar Abhishek Joshi et al.	Brain pseudotumour secondary to Behçet's disease	2019
Emeritus Professor Nicol Ferrier Professor John Isaacs Dr John Mansfield Professor Allan Young	Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data	2019
Dr Amy Anderson Dr Nicola Maney Dr Dennis Lendrem Julie Diboll Dr Philip Brown et al.	Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis	2019
Laura Ridgley Dr Amy Anderson Dr Nicola Maney Najib Naamane Andrew Skelton et al.	IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function	2019
Professor John Isaacs	Keratinocyte growth factor impairs human thymic recovery from lymphopenia	2019
Dr Matthew Wood Adam Leckenby Dr Gary Reynolds Dr Rachel Spiering Dr Arthur Pratt et al.	Macrophage proliferation distinguishes 2 subgroups of knee osteoarthritis patients	2019
Professor John Isaacs Kundan Iqbal	Potential Pharmacologic Targets for the Prevention of Rheumatoid Arthritis	2019
Dr Ken Baker Andrew Skelton Dr Dennis Lendrem Adam Scadeng Dr Ben Thompson et al.	Predicting drug-free remission in rheumatoid arthritis: A prospective interventional cohort study	2019
Kundan Iqbal Dr Dennis Lendrem Ben Hargreaves Professor John Isaacs Dr Ben Thompson et al.	Routine musculoskeletal ultrasound findings impact diagnostic decisions maximally in autoantibody-seronegative early arthritis patients	2019
Dr Jessica Tarn Dr Nadia Howard-Tripp Dr Dennis Lendrem Andrew Skelton Dr Katherine James et al.	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials	2019
Dr Rachel Spiering Matthew Wood Anshor Fath Oliver Eltherington Dr Amy Anderson et al.	Targeting of tolerogenic dendritic cells to heat-shock proteins in inflammatory arthritis	2019
Dr Chijioke Mosanya Professor John Isaacs	Tolerising Cellular Therapies: What Is Their Promise for Autoimmune Disease?	2019
Professor John Isaacs	Biologic refractory disease in rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis	2018
Dr Nishanthi Thalayasingam Andrew Skelton Dr Amy Anderson Alex Clark Julie Diboll et al.	CD4+ and B lymphocyte expression quantitative traits at rheumatoid arthritis risk loci in untreated early arthritis: implications for causal gene identification	2018
Professor John Isaacs	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis	2018
Dr Ken Baker Dr Ben Thompson Dr Dennis Lendrem Dr Arthur Pratt Professor John Isaacs et al.	Lack of association between clinical and ultrasound measures of disease activity in rheumatoid arthritis clinical remission: a cross-sectional analysis	2018
Professor John Isaacs	Lessons learnt from a discontinued randomised controlled trial: adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica (Subcutaneous Injection of Adalimumab Trial compared with Control: SCIATiC)	2018
Dr Rachel Spiering Professor John Isaacs Professor Catharien Hilkens Dr Phillip Lord	Minimum information about T regulatory cells: A step toward reproducibility and standardization	2018
Dr Ken Baker Professor John Isaacs	Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?	2018
Dr Faye Cooles Dr Amy Anderson Andrew Skelton Dr Arthur Pratt Professor Iain McInnes et al.	Phenotypic and transcriptomic analysis of peripheral blood plasmacytoid and conventional dendritic cells in early drug naïve rheumatoid arthritis	2018
Dr Ken Baker Dr Dennis Lendrem Dr Ben Thompson Dr Arthur Pratt Professor John Isaacs et al.	Predictors of drug-free remission in rheumatoid arthritis: results from the prospective Biomarkers of Remission in Rheumatoid Arthritis (BioRRA) Study	2018
Dr Rachel Spiering Professor John Isaacs Professor Catharien Hilkens	Targeting of tolerogenic dendritic cells towards heat-shock proteins: A novel therapeutic strategy for autoimmune diseases?	2018
Dr Bridget Griffiths Professor John Isaacs	The EuroMyositis registry: An international collaborative tool to facilitate myositis research	2018
Sarah Brockbank Dr Carl Goodyear Dr Ayako Pedersen Professor John Isaacs Philip Stocks et al.	The RA-MAP Consortium: a working model for academia-industry collaboration	2018
Dr Fiona Rayner Professor John Isaacs	Therapeutic tolerance in autoimmune disease	2018
Dr Ken Baker Professor John Isaacs	To taper or not to taper non biological DMARDs in RA remission?	2018
Professor John Isaacs	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis	2017
Dr Gillian Bell Dr Amy Anderson Julie Diboll Oliver Eltherington Dr Rachel Harry et al.	Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis	2017
Professor John Isaacs	Clinical trials of biosimilars should become more similar	2017
Helen Hanson Dr Nicola O'Brien Dr Paul Whybrow Professor John Isaacs Dr Tim Rapley et al.	Drug breakthrough offers hope to arthritis sufferers: qualitative analysis of medical research in UK newspapers	2017
Professor John Isaacs	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort	2017
Professor Karim Raza Dr Arthur Pratt Helen Hanson Dr Stefan Siebert Professor John Isaacs et al.	Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research	2017
Dr Ken Baker Dr Arthur Pratt Dr Ben Thompson Professor John Isaacs	Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers	2017
Professor John Isaacs	Subcutaneous injection of Adalimumab Trial compared with Control (SCIATiC): A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica	2017
Professor John Isaacs Dr Arthur Pratt	Synovial tissue research: A state-of-the-art review	2017
Dr Faye Cooles Dr Amy Anderson Dr Dennis Lendrem Julie Norris Dr Arthur Pratt et al.	The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy	2017
Professor John Isaacs Professor Fiona Matthews	The MRC Framework for the Development, Design and Analysis of Stratified Medicine Research: Enabling Stratified, Precision and Personalised Medicine	2017
Professor John Isaacs	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort	2017
Dr Amy Anderson Dr David Swan Oliver Eltherington Dr Arthur Pratt Dr Gary Reynolds et al.	Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4⁺ T-cells partly via TGF-β1	2017
Joseph Cowell Matthew Buck Rebecca Clarke Professor Waldemar Vollmer Dr Daniela Vollmer et al.	Traceless-Cleavage of Protein-Biotin Conjugates Under Biologically-Compatible Conditions	2017
Dr Arthur Pratt Dr Amy Anderson Professor John Isaacs	Bcl-3 in CD4+ T Cell–Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al	2016
Professor John Isaacs	Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody	2016
Dr Arthur Pratt Dr Amy Anderson Professor John Isaacs Julie Diboll Dr Nishanthi Thalayasingam et al.	Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23	2016
Professor Ioakim Spyridopoulos Dr Carmen Martin-Ruiz Professor Catharien Hilkens Mohammad Yadegarfar Professor John Isaacs et al.	CMV-seropositivity and T-cell senescence predict increased cardiovascular mortality in octogenarians - results from the Newcastle 85+ study	2016
Dr Arthur Pratt Dr Dennis Lendrem Ben Hargreaves Professor John Isaacs	Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data	2016
Professor Christopher Buckley Professor John Isaacs	Cytokines in rheumatoid arthritis - shaping the immunological landscape	2016
Professor John Isaacs	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels	2016
Professor John Isaacs	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis	2016
Helen Hanson Professor John Isaacs Dr Lesley Kay Dr Dennis Lendrem Dr Nicola O'Brien et al.	Experiences of staff and patients in relation to clinical research recruitment and involvement: a qualitative study	2016
Dr Arthur Pratt Dr Amy Anderson Julie Diboll Andrew Skelton Dr Dennis Lendrem et al.	Identification of novel expression quantitative trait loci in CD4+ T cells of untreated early arthritis patients	2016
Professor John Isaacs	Identifying factors which influence the selection of anti-TNF treatment in patients with rheumatoid arthritis in England	2016
Dr Amy Anderson Dr Arthur Pratt Dr John Doran Christine Routledge Ben Hargreaves et al.	IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anti-citrullinated peptide antibody-negative rheumatoid arthritis	2016
Dr Faye Cooles Dr Amy Anderson Dr Rachel Harry Julie Diboll Lee Munro et al.	Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies	2016
Dr Philip Brown Dr Arthur Pratt Professor John Isaacs	Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers	2016
Dr Phillip Lord Dr Rachel Spiering Dr Amy Anderson Julie Diboll Emeritus Professor Lindsay Marshall et al.	Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapies	2016
Professor John Isaacs	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis	2016
Professor John Isaacs	Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.	2016
Dr Gary Reynolds Dr Arthur Pratt Dr David Coady Dr Graham Raftery Dr Alice Lorenzi et al.	Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis	2016
Dr Dennis Lendrem Dr Clare Lendrem Matt Linsley Ruth Rowland-Jones Fabio D'Agostino et al.	Teaching Examples for the Design of Experiments: Geographical Sensitivity and the Self-Fulfilling Prophecy	2016
Dr Ken Baker Benjamin Thompson Dr Dennis Lendrem Dr Arthur Pratt Professor John Isaacs et al.	Ultrasound measures of synovitis are independent of clinical parameters in the setting of rheumatoid arthritis remission: a cross-sectional analysis.	2016
Dr Gary Reynolds Dr Paul Milne Dr Venetia Bigley Professor Matthew Collin Professor John Isaacs et al.	Use of the dendritic cell marker, B and T lymphocyte attenuator, to identify functionally distinct subsets of human CD1c+ dendritic cells	2016
Dr Katherine James Shereen Al-Ali Dr Jessica Tarn Dr Simon Cockell Dr Colin Gillespie et al.	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren’s Syndrome	2015
Professor John Isaacs	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response	2015
Professor John Isaacs	Clinical Utility and Factors Associated with Certolizumab Pegol Drug Levels and Anti-Drug Antibodies in the Long-Term Treatment of Rheumatoid Arthritis	2015
Professor John Isaacs	Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis	2015
Professor John Isaacs	Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis	2015
Dr Arthur Pratt Ben Hargreaves Dr Dennis Lendrem Professor John Isaacs	Components of treatment delay in rheumatoid arthritis differ according to autoantibody status	2015
Professor John Isaacs	Decade in review—clinical rheumatology: 10 years of therapeutic advances in the rheumatic diseases	2015
Dr Alice Lorenzi Professor John Isaacs	Defective removal of ribonucleotides from DNA promotes systemic autoimmunity	2015
Dr Alice Lorenzi Professor John Isaacs	Defective removal of ribonucleotides from DNA promotes systemic lupus erythematosus	2015
Professor John Isaacs	Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial	2015
Shereen Al-Ali Dr Jessica Tarn Dr Simon Cockell Dr Colin Gillespie Professor John Isaacs et al.	Gene Set Enrichment Analysis Across Multiple Expression Studies Reveals a Core Subset of Primary Sjögren's Syndrome-Related Genes	2015
Professor John Isaacs	Genome-Wide Transcriptional Profiling of Rheumatoid Arthrits Patients: Towards Stratified Medicine	2015
Dr Arthur Pratt Professor John Isaacs	Genotyping in rheumatoid arthritis: a game changer in clinical management?	2015
Professor John Isaacs	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort	2015
Professor John Isaacs	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples	2015
Professor John Isaacs	Investigation of Genetic Variants in Predicting Response to Biologic Drugs Used to Treat Rheumatoid Arthritis	2015
Dr Dennis Lendrem Dr Clare Lendrem Dr David Woods Ruth Rowland-Jones Professor John Isaacs et al.	Lost in Space: Design of Experiments and Scientific Exploration in a Hogarth Universe	2015
Professor John Isaacs	Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 Predict Disease Severity, Mortality and Treatment Response in Rheumatoid Arthritis—Multi-Centre Prospective Cohort Studies	2015
Dr Dennis Lendrem Dr Clare Lendrem Professor John Isaacs	Progression-seeking bias and rational optimism in research and development	2015
Dr Arthur Pratt Ben Hargreaves Christine Routledge Lesley Tiffin Julie Norris et al.	Reasons for Treatment Delay in Early Rheumatoid Arthritis Differ According to Autoantibody Status	2015
Dr Kenneth Baker Professor John Isaacs Dr Ben Thompson	Restoring or Threatening a Normal Life: Withdrawing Medication from Patients with Rheumatoid Arthritis in Remission	2015
Dr Ken Baker Professor John Isaacs Dr Ben Thompson	Restoring or Threatening a Normal Life: Withdrawing Medication from Patients with Rheumatoid Arthritis in Remission	2015
Dr Faye Cooles Dr Arthur Pratt Dr Dennis Lendrem Professor Fai Ng Dr Terry Aspray et al.	Retrospective analysis of the role of serum vitamin D in early rheumatic disease	2015
Professor John Isaacs	Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study	2015
Dr Philip Brown Professor John Isaacs	Rheumatoid Arthritis: An Evolutionary Force in Biologics	2015
Dr Laura Jopson Emerita Professor Julia Newton Dr Jeremy Palmer Achilleas FLOUDAS Professor John Isaacs et al.	RITPBC: B-Cell Depleting Therapy (rituximab) as a treatment for fatigue in Primary Biliary Cirrhosis: study protocol for a randomised controlled trial	2015
Dr Laura Jopson Emerita Professor Julia Newton Denise Howel Dr Jeremy Palmer Professor John Isaacs et al.	RITPBC: B-cell depleting therapy (RITUXIMAB) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial	2015
Dr Arthur Pratt Dr Amy Anderson Dr Dennis Lendrem Julie Diboll Ben Hargreaves et al.	STAT3-regulated gene expression in circulating CD4+ T cells discriminates RA patients independently of clinical parameters in early arthritis: a validation study.	2015
Dr Arthur Pratt Dr Amy Anderson Julie Diboll Andrew Skelton Ben Hargreaves et al.	The Importance of IL-6-STAT₃ Mediated Activation of Circulating CD4⁺ T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study	2015
Dr Faye Cooles Dr Amy Anderson Professor Catharien Hilkens Professor John Isaacs	The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity	2015
Dr Dennis Lendrem Dr Clare Lendrem Professor John Isaacs	Why is it hard to terminate failing projects in pharmaceutical R&D?	2015
Harriet Purvis Dr Amy Anderson Professor David Young Professor John Isaacs Professor Catharien Hilkens et al.	A Negative Feedback Loop Mediated by STAT3 Limits Human Th17 Responses	2014
Professor John Isaacs Emerita Professor Helen Foster	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort	2014
Dr Gillian Bell Dr Amy Anderson Julie Diboll Dr Rachel Harry Emerita Professor Elaine McColl et al.	Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis.	2014
Dr Gillian Bell Dr Amy Anderson Dr Rachel Harry Julie Diboll Emerita Professor Elaine McColl et al.	Autologous tolerogenic dendritic cells in rheumatoid and inflammatory arthritis	2014
Professor John Isaacs	Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials	2014
Dr Dennis Lendrem Andrew Gray Professor John Isaacs	Christmas 2014: Going to Extremes. The Darwin Awards: sex differences in idiotic behaviour	2014
Professor John Isaacs	Correlating whole genome expression profiling with treatment response in rheumatoid arthritis patients	2014
Professor John Isaacs	Differential DNA Methylation Related to Response to Adalimumab and Etanercept in Patients with Rheumatoid Arthritis	2014
Professor John Isaacs	Effect of inadequate adherence on clinical outcomes: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort	2014
Professor John Isaacs	Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial	2014
Dr Gary Reynolds Dr Faye Cooles Professor John Isaacs Professor Catharien Hilkens	Emerging immunotherapies for rheumatoid arthritis	2014
Professor John Isaacs	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment	2014
Sophie Noblett Dr Arthur Pratt Ben Hargreaves Christine Routledge Phil Mawson et al.	IL-6 Driven Stat3 Phophorylation in Circulating Lymphocytes is Specifiv for CD4⁺ T Cells in Early Rheumatoid Arthritis	2014
Professor John Isaacs	Impact of Inadequate Adherence on Clinical Outcomes: Results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort	2014
Professor John Isaacs Emerita Professor Helen Foster	Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis	2014
Professor John Isaacs	Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A UK-Based Prospective Study	2014
Professor John Isaacs	Influence of Immunogenicity on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab: A UK-Based Prospective Study	2014
Dr Amy Anderson Christine Routledge Professor John Isaacs Dr Arthur Pratt	Investigation of interleukin-6-driven STAT3 signalling in circulating lymphocytes of patients with early rheumatoid arthritis as a route to biomarker discovery	2014
Professor John Isaacs	Personalized Genetic Medicine: Amino Acid Positions 11, 71 and 74 in HLA-DRB1 PREDICT Disease Severity, Treatment Response and Mortality in Rheumatoid Arthritis; Multi-Centre Prospective Cohort Studies	2014
Dr Amy Anderson Dr Arthur Pratt Ben Hargreaves Philip Brown Professor John Isaacs et al.	Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4⁺ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis	2014
Dr Amy Anderson Dr Arthur Pratt Ben Hargreaves Philip Brown Professor John Isaacs et al.	Phospho-STAT1/3 measurement in circulating CD4+T-cells as a diagnostic tool in early autoantibody-negative rheumatoid arthritis	2014
Professor John Isaacs	Predicting Response to Etanercept in Rheumatoid Arthritis Patients Using Whole Genome Expression Profiling	2014
Dr Ken Baker Professor John Isaacs	Prospects for therapeutic tolerance in humans	2014
Dr Dennis Lendrem Dr Clare Lendrem Professor John Isaacs	R&D Productivity Rides Again?	2014
Dr Faye Cooles Dr Arthur Pratt Dr Dennis Lendrem Professor Fai Ng Dr Terry Aspray et al.	Retrospective analysis of the role of serum vitamin D in early rheumatic disease	2014
Dr Philip Brown Professor John Isaacs	Rheumatoid arthritis: from palliation to remission in two decades	2014
Dr Arthur Pratt Professor John Isaacs	Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects	2014
Professor John Isaacs	Testing the role of vitamin D in response to antitumour necrosis factor alpha therapy in a UK cohort: a Mendelian randomisation approach.	2014
Professor John Isaacs	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis	2014
Dr Dennis Lendrem Andrew Gray Professor John Isaacs	The Darwin Awards: Gender Differences in Idiotic Behaviour	2014
Dr Arthur Pratt Dr Philip Brown Dr Simon Cockell Gillian Wilson Professor John Isaacs et al.	A CD4+T-Cell Gene Expression Signature Predicts Drug Survival on Methotrexate Monotherapy in Early Rheumatoid Arthritis	2013
Professor John Isaacs	Association Of Mean Changes In Laboratory Safety Parameters With C-Reactive Protein At Baseline and Week 12 In Rheumatoid Arthritis Patients Treated With Tofacitinib	2013
Dr Gillian Bell Dr Amy Anderson Julie Diboll Dr Rachel Harry Emerita Professor Elaine McColl et al.	Autologous Tolerogenic Dendritic Cells In Rheumatoid and Inflammatory Arthritis	2013
Professor John Isaacs	Can CD11c Expression Successfully Predict Response to Etanercept in Rheumatoid Arthritis Patients?	2013
Professor John Isaacs	Differential Methylation Related to Response to Etanercept in Patients with Rheumatoid Arthritis	2013
Professor John Isaacs	Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis	2013
Professor John Isaacs	Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis	2013
Professor John Isaacs	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis	2013
Professor John Isaacs	Impact of IL-6R and IL-6ST Polymorphisms on Response to Anti-TNF Therapy in UK Patients – Results from the Braggss Cohort	2013
Dr Amy Anderson Christine Routledge Phil Mawson Professor John Isaacs Dr Arthur Pratt et al.	Interleukin-6 driven STAT3 phosphorylation in circulating lymphocytes is specific for CD4 T cells in early rheumatoid arthritis	2013
Dr Amy Anderson Christine Routledge Phil Mawson Professor John Isaacs Dr Arthur Pratt et al.	Interleukin-6 Driven STAT3 Phosphorylation In Circulating Lymphocytes Is Specific For CD4⁺ T Cells In Early Rheumatoid Arthritis	2013
Dr Arthur Pratt Dr Alice Lorenzi Gillian Wilson Professor John Isaacs	Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?	2013
Professor John Isaacs	Reduced Clinical Improvement in Rheumatoid Arthritis Patients Showing IgG1 Allotype -Infliximab Incompatibility	2013
Dr Faye Cooles Dr Arthur Pratt Professor Fai Ng Dr Terry Aspray Professor John Isaacs et al.	The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis	2013
Professor John Isaacs	The role of biosimilars in the treatment of rheumatic diseases	2013
Professor John Isaacs	Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: A Randomized Trial	2013
Professor John Isaacs	Tofacitinib, An Oral Janus Kinase Inhibitor: Safety Comparison In Patients With Rheumatoid Arthritis and An Inadequate Response To Nonbiologic Or Biologic Disease-Modifying Anti-Rheumatic Drugs	2013
Professor Catharien Hilkens Professor John Isaacs	Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?	2013
Dr Faye Cooles Professor John Isaacs Dr Amy Anderson	Treg Cells in Rheumatoid Arthritis: An Update	2013
Professor John Isaacs Professor Christopher Buckley	What can rheumatologists learn from translational cancer therapy?	2013
Dr Arthur Pratt Dr Daniel Swan Dr Sarah Richardson Gillian Wilson Professor Catharien Hilkens et al.	A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly anti-citrullinated peptide antibody-negative disease	2012
Dr Arthur Pratt Dr Philip Brown Dr Simon Cockell Gillian Wilson Professor John Isaacs et al.	A CD4+T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis.	2012
Dr Arthur Pratt Dr Alice Lorenzi Gillian Wilson Professor John Isaacs	A Pragmatic Musculoskeletal Ultrasound Screening Protocol Does Not Add to a Predictive Algorithm for Persistent Inflammatory Arthritis in a UK Early Arthritis Clinic	2012
Professor Simon Pearce Dr Anna Mitchell Dr Stuart Bennett Professor John Isaacs Dr Bijayeswar Vaidya et al.	Adrenal Steroidogenesis after B Lymphocyte Depletion Therapy in New-Onset Addison's Disease	2012
Dr Gillian Bell Dr Amy Anderson Dr Rachel Harry Dr Jeroen Stoop Professor Catharien Hilkens et al.	Autologous tolerogenic dendritic cells in rheumatoid arthritis	2012
Mark Houseman Dr Kate Potter Nicola Marshall Dr Rachel Lakey Emeritus Professor Tim Cawston et al.	Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up	2012
Professor John Isaacs	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis	2012
Professor John Isaacs	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort	2012
Dawn Hiles Professor John Isaacs	Correlation of CRP haplotypes with response to anti-TNF therapy in UK patients: results from the BRAGGSS cohort	2012
Professor David Deehan Andrew Sprowson Linda Ferguson Dr Nilendran Prathalingam Professor John Isaacs et al.	Differential Release of Heterogeneous Human Mesenchymal Stem Cell Populations from Haemarthrotic Traumatic Knee Injury	2012
Dr Daniel Birchall Emerita Professor Julia Newton Professor Andrew Blamire Professor John Isaacs	Disease activity and cognition in rheumatoid arthritis: an open label pilot study	2012
Professor John Isaacs	Estimating heritability of response to treatment with anti-TNF biologic agents using linear mixed models	2012
Professor John Isaacs	Fc gamma RIIIa Expression on Monocytes in Rheumatoid Arthritis: Role in Immune-Complex Stimulated TNF Production and Non-Response to Methotrexate Therapy	2012
Dr Joanna Collerton Dr Carmen Martin-Ruiz karen Davies Professor Catharien Hilkens Professor John Isaacs et al.	Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: Cross-sectional findings from the Newcastle 85+ Study	2012
Dr Amy Anderson Dr Alice Lorenzi Dr Arthur Pratt Thomas Wooldridge Julie Diboll et al.	Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses	2012
Professor John Isaacs	Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort	2012
Dr Arthur Pratt Dr Sarah Richardson Gillian Wilson Professor Catharien Hilkens Professor David Young et al.	A Transcriptional Profile Present in CD4+T-Cells of Patients with Undifferentiated Arthritis Predicts the Future Development of Seronegative Rheumatoid Arthritis and Implicates IL-6 in Disease Evolution	2011
Professor John Isaacs	Anti-TNF therapy	2011
Dr Gillian Bell Dr Gary Reynolds Professor John Isaacs	Biologic therapies in non-rheumatic diseases: lessons for rheumatologists?	2011
Dr Arthur Pratt Dr Alice Lorenzi Dr Philip Platt Professor John Isaacs	Does routine musculoskeletal ultrasound use add value to the diagnosis of a RA among early and undifferentiated arthritis patients?	2011
Dr Arthur Pratt Professor John Isaacs	Does testing for circulating autoantibodies against disease-relevant citrullinated antigens add value to the CCP2 assay in diagnosing RA among early undifferenitated arthritis patients?	2011
Dr Arthur Pratt Professor John Isaacs	Does testing for circulating autoantibodies against disease-relevant citrullinated antigens add value to the CCP2 assay in diagnosing RA among early undifferentiated arthritis patients?	2011
Professor John Isaacs Dr Jo Lee	Effect of Tocilizumab on Hematologic Markers Implicates Interleukin-6 Signaling in the Anemia of Rheumatoid Arthritis	2011
Dr Ismael Atchia Dr David Kane Michael Reed Professor John Isaacs Professor Fraser Birrell et al.	Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis	2011
Dr Faye Cooles Professor Graham Jackson Professor John Isaacs	Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis	2011
Professor John Isaacs	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients	2011
Dr Kate Potter Professor John Isaacs	Genome-Wide Association Study of Genetic Predictors of Anti-Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations With Polymorphisms at Seven Loci	2011
Professor John Isaacs	Integrated safety in tocilizumab clinical trials	2011
Dr Faye Cooles Professor John Isaacs	Pathophysiology of rheumatoid arthritis	2011
Dr Faye Cooles Dr Arthur Pratt Dr Gillian Wilson Professor John Isaacs Professor Fai Ng et al.	Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months	2011
Dr Arthur Pratt Professor John Isaacs	Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort	2011
Professor John Isaacs	The need for personalised medicine for rheumatoid arthritis	2011
Professor John Isaacs	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis	2011
Dr Joanna Cunnington Dr Geoff Hide Dr Claire Bracewell Professor John Isaacs Dr Philip Platt et al.	A randomized, double-blind, controlled study of ultrasound-guided corticosteroid injection into the joint of patients with inflammatory arthritis	2010
Dr Kate Potter Professor Heather Cordell Professor Ann Daly Professor Derek Mann Professor John Isaacs et al.	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFĸB signalling pathways	2010
Professor Catharien Hilkens Professor John Isaacs	Development of dendritic cell-based immunotherapy for autoimmunity	2010
Professor John Isaacs	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease	2010
Dr Faye Cooles Professor Graham Jackson Professor John Isaacs	EBV driven lymphoproliferative disease following alemtuzumab (CAMPATH-1H) in refractory polymyositis	2010
Professor John Isaacs	Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))	2010
Dr Rachel Harry Dr Amy Anderson Professor John Isaacs Professor Catharien Hilkens	Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis	2010
Emeritus Professor Nicol Ferrier Professor John Isaacs Dr John Mansfield Professor Mark Walker	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls	2010
Professor Fai Ng Professor John Isaacs	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis	2010
Dr Kate Potter Professor John Isaacs	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment	2010
Harriet Purvis Dr Jeroen Stoop Professor Jelena Mann Steven Woods Anne Kozijn et al.	Low strength T-cell activation promotes Th17 responses	2010
Dr Jeroen Stoop Professor Jelena Mann Steven Woods Anne Kozijn Professor Sophie Hambleton et al.	Low-strength T-cell activation promotes Th17 responses	2010
Dr Arthur Pratt Dr Daniel Swan Dr Sarah Richardson Professor Catharien Hilkens Professor David Young et al.	Peripheral Blood CD4 T Cell Gene Expression Profiles as Predictive Biomarkers in Early Arthritis	2010
Professor Heather Cordell Professor John Isaacs	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response	2010
Dr Susan Tudhope Dr Alexei von Delwig Dr Jane Falconer Dr Arthur Pratt Professor John Isaacs et al.	Profound invariant natural killer T-cell deficiency in inflammatory arthritis	2010
Professor John Isaacs	Rheumatoid Arthritis Risk Allele PTPRC Is Also Associated With Response to Anti-Tumor Necrosis Factor alpha Therapy	2010
Professor John Isaacs	Rheumatoid factor (RF) oranti-cyclic citrullinated peptide (aCCP) seropositivity in rheumatoid arthritis (RA) patients may enhance clinical response to rituximab	2010
Professor John Isaacs	Rituximab plus Methotrexate (MTX) is effective in a subset of patients with early rheumatoid arthritis (RA) and characteristics associated with poor outcomes: an analysis from the image study	2010
Professor John Isaacs	The changing face of rheumatoid arthritis: sustained remission for all?	2010
Dr Jeroen Stoop Dr Rachel Harry Dr Alexei von Delwig Professor John Isaacs Professor John Robinson et al.	Therapeutic Effect of Tolerogenic Dendritic Cells in Established Collagen-Induced Arthritis Is Associated With a Reduction in Th17 Responses	2010
Professor John Isaacs	Tolerogenic dendritic cells: a new treatment for rheumatoid arthritis?	2010
Professor John Isaacs Professor Patrick Chinnery	Translating cutting edge science into novel and effective therapies	2010
Dr Faye Cooles Professor John Isaacs	Treating to re-establish tolerance in inflammatory arthritis - lessons from other diseases	2010
Helen Baldwin Dr Toshiko Ihara Professor John Isaacs Professor Catharien Hilkens	Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis	2010
Professor John Isaacs	[Meeting Abstract] Cost Effectiveness of Biological Therapeutic Sequences for Rheumatoid Arthritis in the UK	2009
Dr Arthur Pratt Dr Daniel Swan Professor David Young Professor Catharien Hilkens Professor John Isaacs et al.	A High-Throughput Transcriptomics Approach to Biomarker Discover in Early Arthritis	2009
Dr Rachel Lakey Emeritus Professor Drew Rowan Professor John Isaacs Emeritus Professor Tim Cawston Professor Catharien Hilkens et al.	A novel paradigm for dendritic cells as effectors of cartilage destruction	2009
Professor John Isaacs	Animal models in infection and inflammation - Chance and necessity	2009
Professor John Isaacs	Antibody engineering to develop new antirheumatic therapies	2009
Dr Kate Potter Professor John Isaacs	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis	2009
Dr Claire Bracewell Professor John Isaacs Professor Fai Ng	Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis	2009
Julie Diboll Professor John Isaacs Professor Fai Ng	CD4+T Cell Responses to Autoantigens in Patients with Rheumatoid Arthritis	2009
Dr Alice Lorenzi Dr Angela Patterson Dr Arthur Pratt Dr Matthew Jefferson Professor John Isaacs et al.	Corrigendum to "Determination of thymic function directly from peripheral blood: A validated modification to an established method" [J. Immunol. Methods 2008 339(2):185-94] (DOI:10.1016/j.jim.2008.09.013)	2009
Dr Arthur Pratt Professor John Isaacs	Current concepts in the pathogenesis of early rheumatoid arthritis	2009
Dr Kate Potter Professor John Isaacs	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients	2009
Dr Amy Anderson Dr David Swan Bethan Sayers Dr Rachel Harry Dr Angela Patterson et al.	LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells	2009
Dr Ismael Atchia Dr David Kane Michael Reed Professor John Isaacs Professor Fraser Birrell et al.	Musculoskeletal ultrasound predicts predicts response to corticosteroid injection in moderate-severe hip osteoarthritis	2009
Professor John Isaacs Dr Amy Anderson	Regulatory T cells and autoimmunity	2009
Emeritus Professor David Bates Professor John Isaacs	Should neurologists wait and see or see and treat RRMS?	2009
Dr Arthur Pratt Professor John Isaacs	The clinical utility of a rule for predicting rheumatoid arthritis in patients with early undifferentiated arthritis: comment on the article by van der Helm-van Mil et al	2009
Professor John Isaacs	Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists	2009
Dr Alice Lorenzi Emerita Professor Helen Foster Professor John Isaacs	Thymic function and immune senescence in juvenile idiopathic arthritis: comment on the article by Prelog et al	2009
Dr Alice Lorenzi Dr Amy Anderson Dr Jonathan Catterall Dr Angela Patterson Emerita Professor Helen Foster et al.	Thymic function in juvenile idiopathic arthritis	2009
Dr Kate Potter Professor John Isaacs	Variation in the CD226 Gene Predicts Response to Anti-TNF Therapy in Rheumatoid Arthritis	2009
Professor John Isaacs	Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the 'age of remission'?	2009
Professor John Isaacs	A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis	2008
Alistair Brown Professor Jaap Van Laar Professor John Isaacs	Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse.	2008
Dr Ben Thompson Dr James Miller Professor John Isaacs	Alemtuzumab (Campath-1H) for treatment of refractory polymyositis	2008
Dr Kate Potter Professor John Isaacs	Association of the tumour necosis factor -308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis	2008
Dr Kate Potter Professor John Isaacs	Complex genetic relationship of the TNF locus with response to anti-TNF agents in the treatment of rheumatoid arthritis	2008
Emeritus Professor Mike Sir Michael Rawlins Dr Angela Patterson Dr Arthur Pratt Dr Matthew Jefferson Professor John Isaacs et al.	Determination of thymic function directly from peripheral blood: a validated modification to an established method	2008
Dr Rachel Harry Dr Amy Anderson Dr Graham Raftery Professor John Isaacs Professor Catharien Hilkens et al.	Development of clinical-grade tolerogenic dendritic cells for the treatment of rheumatoid arthritis	2008
Dr Amy Anderson Bethan Sayers Professor Muzlifah Haniffa Dr David Swan Julie Diboll et al.	Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells	2008
Dr Mahmad Atchia Dr David Kane Professor John Isaacs Professor Fraser Birrell	Efficacy of a single ultrasound guided injection in hip osteoarthritis	2008
Professor John Isaacs	FCGR3A is associated with autoantibody positive rheumatoid arthritis in a large UK Caucasian population	2008
Professor John Isaacs	From bench to bedside in rheumatology - seize the moment	2008
Dr Kate Potter Professor John Isaacs	Identification of single nucleotide polymorphisms associated with response to anti-tumour necrosis factor treatment	2008
Dr Jeroen Stoop Dr Alexei von Delwig Professor John Isaacs Professor John Robinson Professor Catharien Hilkens et al.	Immunotherapy with tolerogenic dendritic cells inhibits the progression of collagen-induced arthritis	2008
Dr Alexei von Delwig Dr Arthur Pratt Dr Susan Tudhope Professor John Isaacs Professor Fai Ng et al.	Invariant natural killer T (iNKT) cells in early rheumatoid arthritis (RA)	2008
Dr Alice Lorenzi Professor John Isaacs	Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes	2008
Professor John Isaacs	Rituximab and abatacept for rheumatoid arthritis	2008
Dr Alexei von Delwig Dr Susan Tudhope Dr Arthur Pratt Professor John Isaacs Dr Desa Lilic et al.	The role of invariant natural killer T (iNKT) cells in rheumatoid arthritis	2008
Professor John Isaacs	The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab)	2008
Professor John Isaacs	Therapeutic T-cell manipulation in rheumatoid arthritis: Past, present and future	2008
Dr Alice Lorenzi Emerita Professor Helen Foster Professor John Isaacs	Thymic function and immune senescence in juvenile idiopathic arthritis	2008
Dr Alice Lorenzi Dr Amy Anderson Dr Jonathan Catterall Dr Angela Patterson Emerita Professor Helen Foster et al.	Thymic function in juvenile idiopathic arthritis	2008
Dr Amy Anderson Bethan Sayers Dr David Swan Professor John Isaacs Professor Catharien Hilkens et al.	Tolerogenic dendritic cell therapy for rheumatoid arthritis	2008
Dr Amy Anderson Professor John Isaacs	Tregs and rheumatoid arthritis	2008
Professor Muzlifah Haniffa Dr Xiao Wang Dr Udo Holtick Dr Michelle Rae Professor John Isaacs et al.	Adult Human Fibroblasts Are Potent Immunoregulatory Cells and Functionally Equivalent to Mesenchymal Stem Cells	2007
Professor John Isaacs	Biologic therapies in rheumatology: Lessons learned, future directions	2007
Dr Mohammed Ali Professor John Isaacs	Differential display reverse transcription-polymerase chain reaction to identify novel biomolecules in arthritis research	2007
Professor Fai Ng Professor John Isaacs	From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic	2007
Professor Fai Ng Professor John Isaacs	From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic	2007
Bethan Sayers Professor Muzlifah Haniffa Julie Diboll Professor John Isaacs Professor Catharien Hilkens et al.	Generation of dexamethasone and vitamin D3-treated human monocyte-derived dendritic cells with tolerogenic properties	2007
Dr Xiao Wang Dr Udo Holtick Suzanne Alshemali Professor Nick Reynolds Professor Anne Dickinson et al.	Human dermal broblasts ameliorate in vitro graft-versushost reactions and are functionally indistinguishable from bone marrow mesenchymal stromal cells	2007
Professor John Isaacs	Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors	2007
Professor Mark Walker Professor John Isaacs	Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes	2007
Professor John Isaacs	T cell immunomodulation-the Holy Grail of therapeutic tolerance	2007
Dr Alexei von Delwig Dr Fraser Charlton Professor John Isaacs Professor John Robinson	T cell responses to a non-glycosylated epitope predominate in type II collagen-immunised HLA-DRB1*0101 transgenic mice	2007
Professor John Isaacs	Targeting B cells across the rheumatic diseases	2007
Dr Amy Anderson Bethan Sayers Julie Diboll Professor John Isaacs Professor Catharien Hilkens et al.	Tolerogenic dendritic cells differentially modulate naïve and memory CD4⁺ T cells	2007
Professor John Allen Elizabeth Kokkinos Emeritus Professor Alan Murray Emeritus Professor Brian Diffey Dr Simon Meggitt et al.	Assessment of skin fluorescence characteristics in systemic sclerosis	2006
Professor John Isaacs	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis	2006
Alistair Brown Professor John Isaacs	Early rheumatoid arthritis is associated with a deficit in the CD4⁺CD25^high regulatory T cell population in peripheral blood	2006
Dr Alexei von Delwig Professor John Isaacs Professor Jeremy Lakey Professor John Robinson	Febrile temperatures enhance antigen processing of type II collagen for presentation to CD4 T cells.	2006
Dr Deborah Thomas Professor John Isaacs Dr Peter Hamilton	Guidelines on the management of massive blood loss	2006
Alistair Brown Professor John Isaacs	IL-7 modulates CD4(+)CD25(high) regulatory T-cell function	2006
Professor John Isaacs Dr Peter Dawes	Improved quality of life with rituximab plus methotrexate in patients with active rheumatoid arthritis who experienced inadequate response to one or more anti-TNF alpha therapies	2006
Dr Alexei von Delwig Professor Catharien Hilkens Professor John Isaacs Dr Helen Robertson Professor John Robinson et al.	Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice	2006
Dr Alice Lorenzi Dr Angela Patterson Professor John Isaacs	Measuring thymic function in systemic lupus erythematosus	2006
Alistair Brown Professor John Isaacs	Molecualr mechanism for the accumulation of abnormal T-cells in RA patients in clinical remission: Late atypical cells	2006
Alistair Brown Professor John Isaacs	Molecular mechanism for the persistence of abnormal T-cells in RA patients in clinical remission: Inflammation related cells	2006
Professor John Isaacs	Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to tnf inhibitors	2006
Professor John Isaacs	Repeat treatment with rituximab improves physical function and quality of life in patients with rheumatoid arthritis and an inadequate response to TNF inhibitors	2006
Professor John Isaacs	Rheumatology Highlights 2005-06	2006
Dr Alexei von Delwig Professor John Isaacs Dr Norman Balfour-McKie Professor John Robinson	The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model	2006
Professor Simi Ali Dr Helen Robertson Professor John Isaacs Emeritus Professor John Kirby	A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation	2005
Dr Alice Lorenzi Dr Angela Patterson Professor John Isaacs	A revised assay for the measurement of T-cell receptor excision circles as a quantitative measure of thymic function in systemic lupus erythematosus	2005
Alistair Brown Professor John Isaacs	A role for IL-7 in regulating CD4(+)CD25(high) regulatory T cells	2005
Alistair Brown Professor John Isaacs	A role for IL-7 in regulating CD4(+)CD25(high) regulatory T cells	2005
Dr Bridget Griffiths Professor John Isaacs	Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis - Results of a pilot safety study	2005
Dr Bridget Griffiths Professor John Isaacs	Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B	2005
Professor John Isaacs	Analysis of the insertion/deletion related polymorphism within T cell antigen receptor β variable genes in primary Sjögren's syndrome	2005
Professor John Isaacs	Association of FCGR2A and FC gamma R haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis	2005
Professor John Isaacs	Association of FCGR2A and Fc gamma receptor haplotypes with Spanish polymyalgia rheumatica and giant cell arteritis	2005
Professor John Isaacs	Association of FCGR3A and FCGR3B haplotypes with rheumatoid arthritis and primary Sjogren's syndrome	2005
Dr Alice Lorenzi Professor John Isaacs Dr Desa Lilic	CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy [1]	2005
Bethan Sayers Professor Muzlifah Haniffa Julie Diboll Professor John Isaacs Professor Catharien Hilkens et al.	Generation of dexamethasone and vitamin D3 treated human monocyte derived dendritic cells with tolerogenic properties	2005
Dr Alexei von Delwig Professor John Isaacs Professor John Robinson	Human type II collagen is processed in lysosomal compartments of macrophages for presentation of the glycosylated arthritogenic epitope hCII(259-273) to CD4 T cells in HLA-DR1 transgenic mice	2005
Professor John Isaacs	Improvement of T-cell function in RA patients in clinical remission is associated with the recovery of IL-7 expression and depends on a familial history of RA	2005
Professor John Isaacs	Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis	2005
Professor John Isaacs	Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis	2005
Dr Elspeth Wise Professor John Isaacs	Management of rheumatoid arthritis in primary care - An educational need?	2005
Professor John Isaacs Professor Jaap Van Laar	Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration	2005
Professor John Isaacs	T-bet expression in RA patients with early, DMARDs naive disease is low and correlates with low levels of IL-7 and T-cell dysfunctions	2005
Professor John Isaacs	The persistence of abnormal T-cell differentiation patterns predicts relapse in rheumatoid arthritis patients with controlled disease	2005
Dr Alexei von Delwig Professor John Isaacs Professor John Robinson	The role of uptake and intracellular trafficking of type II collagen in presentation of the glycosylated arthritogenic epitope CII259-273, to CD4 T cells in HLA-DR1 transgenic mice	2005
Professor John Isaacs	The signaling signature downstream of the Notch receptor in CD4+CD25(high) regulatory T-cells in RA defines anergic cells: Insight into resistance to anti-TNF therapies	2005
Professor John Isaacs	The signalling signature downstream of the notch receptor in CD4(+)CD25(high) regulatory T cells in RA defines anergic cells: insight into resistance to anti-tumour necrosis factor therapies	2005
Dr Alice Lorenzi Kathryn Walker Dr Angela Patterson Dr Bridget Griffiths Professor John Isaacs et al.	Thymic function is impaired in patients with a variety of autoimmune diseases	2005
Professor Mark Baker Professor John Isaacs Dr Peter Fawcett Emeritus Professor David Bates	Treatment of stiff person syndrome with rituximab	2005
Professor John Isaacs	Anti-TNFα Therapy Modulates the Phenotype of Peripheral Blood CD4+ T Cells in Patients with Posterior Segment Intraocular Inflammation	2004
Paul Emery Professor John Isaacs	Fcγ receptors are critical modulators of inflammation within the synovium: Comment on the article by Blom et al	2004
Professor John Isaacs	Immune reconstitution	2004
Alistair Brown Dr Prakash Patel Professor Jaap Van Laar Professor John Isaacs	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia	2004
Dr Alexei von Delwig Professor John Isaacs Professor John Robinson	Mechanisms of MHC class II-restricted antigen processing and presentation of human type II collagen in antigen-presenting cells from humanized DR1 transgenic mice	2004
Professor John Isaacs	Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis	2004
Professor John Isaacs	Rheumatology Highlights 2003/04	2004
Professor John Isaacs	Stem cell transplantation for autoimmune disorders: Immune reconstitution	2004
Professor John Isaacs	Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis	2004
Professor John Isaacs	Targeting B cells with rituximab: An effective and well tolerated treatment for active rheumatoid arthritis (RA)	2004
Professor John Isaacs	Association analysis of VDR, alpha-2-macroglobulin, TNFRII, Fc gamma RIIIA and ACE gene polymorphisms in south Asian rheumatoid arthritis patients of the East Midlands, UK	2003
Alistair Brown Professor John Isaacs	CD4+T-Cell TREC-Content in RA Patients in Clinical Remission.	2003
Professor John Isaacs	IL-7 Deficiency and Prolonged Therapy-Induced Lymphopenia in Rheumatoid Arthritis.	2003
Professor John Isaacs	Long-term immunologic effects of alemtuzumab: Immune reconstitution and immune function after alemtuzumab therapy for autoimmune disease	2003
Professor John Isaacs	Neutralizing TNF activity leads to remission in refractory non-infectious uveitis	2003
Tein Leong Professor John Isaacs	Real-time PCR based on SYBR-green flourescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions	2003
Alistair Brown Professor John Isaacs	Rheumatoid Arthritis is Associated With A Deficit in the CD4(+)CD25(high) Regulatory T Cell Population in Peripheral Blood.	2003
Professor Jaap Van Laar Professor John Isaacs	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis	2002
Professor John Isaacs	From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies	2001
Professor Fai Ng Professor John Isaacs	Human CD4⁺CD25⁺ cells: a naturally occurring population of regulatory T cells	2001
Professor John Isaacs	Morbidity and Mortality in Rheumatoid Arthritis Patients With Prolonged and Profound Therapy-Induced Lymphopenia	2001
Professor John Isaacs	Rheumatoid arthritis synovial T cells regulate transcription of several genes associated with antigen-induced anergy	2001
Professor John Isaacs Professor David Jones	The ninety-fifth annual general meeting of the association of physicians of Great Britain and Ireland 2001	2001
Dr Bridget Griffiths Professor John Isaacs	Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups	2000